Published: 6 December 2019

Publications

Recent approvals of medicines containing a new active ingredient

Prescriber Update 40(4): 80
December 2019

For period 16 July 2019 to 15 October 2019.

Trade Name (Active ingredient)	Dose form and strength(s)	Therapeutic area
Fotivda (tivozanib)	Capsule 890 mcg 1340 mcg	Renal cell carcinoma

See the Medsafe website for more information about these medicines. Data sheets of currently marketed medicines are also available.